Hype or Help? Obesity Drug Considerations for Employers
Viewpoints from Sarah Fleming & Erin Milliken Coauthored by Sarah Fleming, PharmD – Senior Pharmacy Benefit Clinical Consultant at PSG, and Erin Milliken, MPH, CHES – Director, Wellbeing and Health Management Solutions at EPIC With obesity impacting over 42% of adults and driving over $173 billion in annual medical costs in the U.S.1, incorporating a holistic wellbeing strategy has become more meaningful than ever to employers. Adding anti-obesity medications, specifically GLP-1s, into this overarching strategy continues to gain momentum Recent regulatory changes have further amplified the pressure on employer health plans to respond. The Food and Drug Administration (FDA …
https://www.epicbrokers.com/insights/weight-loss-drug-glp1-employer-considerations/